公开(公告)号：US20240374813A1

公开(公告)日：2024-11-14

申请号：US18661020

申请日：2024-05-10

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Gregory STERN ,  Nika VARPAHOVSKY ,  Jason O’CONNOR

IPC: A61M5/142 ,  G16H20/17 ,  G16H40/63

Abstract: Exemplary embodiments calculate a user's progress towards maximum adapted system performance when utilizing a drug delivery device such as an insulin pump and display this progress to the user. Further embodiments calculate potential changes to a particular user's interaction with the system given a history of glucose and insulin deliveries and provide guidance to that user. This can be used, for example, to change how the user splits up their basal and bolus doses to improve metrics such as time-in-range, incidences of hyper- or hypo-glycemia, time in hyper- or hypo-glycemia, mean glucose, etc. It may also be used to speed the above-described adaptation process by suggesting changes that the user can make to achieve stability more quickly.

公开(公告)号：US20240066213A1

公开(公告)日：2024-02-29

申请号：US18453765

申请日：2023-08-22

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O’CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/142 ,  A61M5/172

CPC classification number: A61M5/14248 ,  A61M5/1723 ,  A61M2202/0486

Abstract: Disclosed are techniques, devices and systems that modify an insulin delivery schedule based on how sensitive a diabetic user may to fluctuations in their total daily insulin or fluctuations in their blood glucose measurement values. As a control algorithm calculates how to adapt the calculation of the user's total daily insulin, a rate of adaptivity function may be used in the calculation. The rate of adaptivity may depend on a number of factors and the disclosed techniques, devices and systems enable calculation of the rate of adaptivity to provide effective implementation or modification of a diabetic treatment plan.

公开(公告)号：US20240075214A1

公开(公告)日：2024-03-07

申请号：US18450238

申请日：2023-08-15

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Rangarajan NARAYANASWAMI ,  Jason O’CONNOR

IPC: A61M5/315 ,  G16H20/17

CPC classification number: A61M5/31566 ,  G16H20/17

Abstract: Safety and accuracy measures may be provided in a medicament delivery device. The medicament delivery device may be able to identify the inadvertent delivery of duplicate medicament boluses by a user. The exemplary embodiments may set limits for maximum allowable medicament bolus doses and maximum cumulative bolus doses over an interval. The exemplary embodiments may provide automatic meal detection and may use detection of meals in determining whether a user-requested medicament bolus dose should be adjusted or rejected. The exemplary embodiments may facilitate delivery of partial boluses and the delivery of remainders of the boluses contingent on acceptable glucose level trends of the user. The exemplary embodiments may resolve potential conflicts among multiple medicament delivery devices via a broker or by providing a single actor, such as a medicament delivery controller, that has sole control of dosing and delivery of medicament boluses.

公开(公告)号：US20240066224A1

公开(公告)日：2024-02-29

申请号：US18451530

申请日：2023-08-17

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O’CONNOR

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2202/0486 ,  A61M2205/50

Abstract: Exemplary embodiments may apply a transform or filter to analyte level values of the users to make the analyte level values conform with a normal distribution that is symmetric relative to the mean. The transformed or filtered analyte level values may be used by the control system of a medicament delivery device in determining medicament delivery doses. In some embodiments, the medicament is insulin, and the analyte level is a glucose level of a user. In such instances, a logarithmic filter or transform may be applied to the glucose level readings of the user.

公开(公告)号：US20250058042A1

公开(公告)日：2025-02-20

申请号：US18800698

申请日：2024-08-12

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  William WHITELEY ,  Jason O’CONNOR

IPC: A61M5/142

Abstract: The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.

公开(公告)号：US20250018114A1

公开(公告)日：2025-01-16

申请号：US18903653

申请日：2024-10-01

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Jason O’CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/142 ,  G16H20/17 ,  G16H40/67

Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

公开(公告)号：US20230233765A1

公开(公告)日：2023-07-27

申请号：US18190678

申请日：2023-03-27

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2205/502 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2230/63 ,  A61M2230/201

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US20250082842A1

公开(公告)日：2025-03-13

申请号：US18883710

申请日：2024-09-12

Applicant: INSULET CORPORATION

Inventor： John BUSSIERE ,  Joon Bok LEE ,  Yibin ZHENG ,  Ashutosh ZADE ,  Jason O’CONNOR

IPC: A61M5/142 ,  A61M5/172

Abstract: In an aspect, an adhesive patch is presented. The adhesive patch has a top surface configured to adhere to a wearable medical device. The adhesive patch has a bottom surface opposite the top surface, wherein the bottom surface includes an adhesive layer configured to adhere to a user's skin. The adhesive patch has a first perforation extending through the top and bottom surfaces, the first perforation configured to receive a piercing element from the wearable medical device.

公开(公告)号：US20240197990A1

公开(公告)日：2024-06-20

申请号：US18530449

申请日：2023-12-06

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  James CAUSEY ,  Ashutosh ZADE ,  Jason O’CONNOR

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2205/70 ,  A61M2230/201

Abstract: Compensation may be provided for the varying accuracy levels of a sensor over time. As a result of the compensation, the medicament delivery device may perform better. The sensor may provide input to a medicament delivery device, and the input may be used to determine a dose of medicament to be delivered to a user by the medicament delivery device. A degree of inaccuracy of sensor values may be determined based on when in the lifetime a sensor value is generated. Glucose level values read by a glucose monitor, such as a CGM, may be directly modified before being used by an automated insulin delivery (AID) control of an insulin delivery device. The compensation for the inaccuracy of the glucose level values from the glucose monitor instead may be achieved by modifying a weight coefficient of a glucose cost component of a cost function in one example.

公开(公告)号：US20230377706A1

公开(公告)日：2023-11-23

申请号：US18199641

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  William WHITELEY ,  Jason O’CONNOR

IPC: G16H20/10 ,  A61B5/145 ,  A61B5/00 ,  G16H40/63

CPC classification number: G16H20/10 ,  A61B5/14532 ,  A61B5/4839 ,  G16H40/63

Abstract: The exemplary embodiments may dynamically adjust an Insulin on Board (JOB) profile for a user of a medicament delivery system to customize the IOB profile to the user based on recent glucose level history and insulin deliveries rather than use the conventional static IOB profiles that are based on population averages. The exemplary embodiments may calculate a Duration of Insulin Action (DIA) for a user from the customized insulin decay curves. The exemplary embodiments may generate and send notifications to the user to help reduce the DIA of the user and/or to keep the DIA of the user from rising. The exemplary embodiments may aim to not overly constrain insulin delivery due to the contribution of insulin boluses to JOB.